Cambridge University's 54-Year Journey of Innovation Commercialization: From Indifference to Full Commitment

Prior to 1969, British scholars showed little interest in discussions of industry-academia collaboration.

In academic tradition, research has always focused on academic papers and achievements, pursuing pure knowledge and scholarly outcomes rather than translating research findings into commercial products.

It was not until the success story of Stanford and Silicon Valley brought a fresh breeze to academia that this air drifted across the sea to the European continent.

In November 1968, the University of Cambridge’s subcommittee submitted the renowned Mott Report, which proposed leveraging the university’s prestige and strengths to attract enterprises grounded in scientific and technological research to the Cambridge area.

The following year, the University of Cambridge issued《University of Cambridge Research and Development Guidelines》, which explicitly states that “the University of Cambridge can not only leverage its research strengths to drive social development, but also utilize its research outcomes to generate economic benefits.” This venerable institution has pioneered a new path as a “university-corporation.”

Nowadays,Innovation Translation: A Defining Feature of the Current University of Cambridge. Cambridge University has already propped up a long pole, roaming towards where the green grass is greener, laden with a boatful of starlight, singing amidst the dappled brilliance of the stars.

It is reported that over the past 54 years, the University of Cambridge has spawned more than 100 startups based on the commercialization of its scientific research achievements. What, then, has empowered the university to steer its course toward deeper innovation and technology transfer? In this article, VCBeat will analyze the University of Cambridge’s model for innovation and technology transfer, aiming to identify the distinctive features of its commercialization mechanisms.

Located in Cambridge, UK, the University of Cambridge is one of the oldest and most prestigious universities in the world, with a history spanning over 800 years. Over the course of its long existence,“Science and Industry”It is Cambridge’s most cherished academic achievement. As of 2023, the University of Cambridge has cultivated121 Nobel laureates, 11 Fields Medalists, and 7 Turing Award winners。

In the field of life sciences, Nobel laureates include Professor William Campbell, who discovered new therapies for roundworm parasitic infections; Michael Levitt, who discovered that mature cells can be reprogrammed into pluripotent cells; and Martin Evans, who discovered the principle of introducing specific genetic modifications in mice using embryonic stem cells...

Under the leadership of pioneering academic representatives, major discoveries from the Department of Biological Sciences at the University of Cambridge span a wide range of fields, from molecular biology to human health. A closer look at the Department reveals that its research framework is divided intoNine Departments and Four Institutes。

The former encompasses biochemistry, genetics, pathology, pharmacology, physiology, developmental and neuroscience, plant sciences, psychology, veterinary medicine, and zoology; the latter comprises four interdisciplinary research institutes: the Gurdon Institute, the Cambridge Stem Cell Institute, the Sainsbury Laboratory, and the MRC Toxicology Unit.

Behind these nine departments and four institutes lies ““Top Scientists + Comprehensive Research Facilities”research portfolio.

Taking the Gurdon Institute as an example, it was established in 1991 by Nobel laureate John Gurdon. The Gurdon Institute integrates developmental biology and cancer research, boasting more than 240 scientists and 16 research groups. Its research scope covers areas such as breast cancer, brain development, liver regeneration, and leukemia.

Gurdon Institute Research Group

As an institute dedicated to basic research, the Gurdon Institute also ensures that researchers have full access to comprehensive scientific equipment for their work. Currently, the Gurdon Institute is equipped with facilities including imaging systems, super-resolution microscopy, high-performance computing clusters, next-generation sequencing, and flow cytometry.

With world-class scientists and state-of-the-art research facilities, the Gurdon Institute publishes more than 80 papers annually in top-tier journals such as Nature, Science, and Cell, many of which are highly cited as groundbreaking discoveries in their respective fields. Moreover, research conducted at the Gurdon Institute has given rise to 13 start-up companies, including KuDOS Pharmaceuticals, Abcam, Cell Centric, Mission Therapeutics, Gen2 Neuro, and Storm Therapeutics.

Among themCellCentricThe company was incubated based on the research findings of Professor Azim Surani, a pioneer in epigenetics. Since its inception, CellCentric has extensively investigated epigenetic pathways to address diseases. Prior to focusing on the dual histone acetyltransferases p300/CBP, more than 50 potential drug targets had been studied. This strategic choice has paved a clear path for developing effective small-molecule inhibitors and well-defined targeted therapies for cancer treatment.

At the University of Cambridge’s Gurdon Institute, cutting-edge research findings do not remain confined to academic papers.

Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, once stated: “Cambridge is a truly exceptional place, where leading scientists work side by side with industry and academic partners to spark ideas and create life-changing medicines, technologies, and services.”It has once again been recognized as one of the greatest innovation hubs on Earth.。”

For instance, it enjoys worldwide renown alongside Silicon Valley in the United States and is known as the “Silicon Fen.”Cambridge Science Park, the park has seen a surge of high-tech enterprises centered around the University of Cambridge and its surrounding areas.

From this perspective, a distinctive transformation strategy of the University of Cambridge is “identifying a vehicle,”Leveraging basic research as a foundation, we pool the strengths of universities, government, and industry to streamline the pathway for translating scientific achievements into practical applications.

In 1970, Trinity College, University of Cambridge, decided to leverage its traditional strengths in science and innovation to accelerate the commercialization of research achievements. Consequently, a 24-acre plot was designated in the northwest corner of the city, three miles from the city center, establishing the original Cambridge Science Park.

Leveraging the University of Cambridge’s applied research capabilities, Cambridge Science Park conducts research and development in biomedicine, artificial intelligence, software, new materials, and new energy. Within the innovation network, Cambridge Science Park serves as both a source of origination and a hub for commercialization. To date, the park is home to more than 170 companies and over 7,000 employees, with 61% of the enterprises originating from the University of Cambridge.

In addition to support from universities, the success of Cambridge Science Park also lies in its ability to bring togetherFactor Clusters and Industrial Agglomeration。

The so-called factor cluster refers toInnovation Factors (Basic Research at the University of Cambridge) and Management Service Factors. The input of management elements also determines the prospects of the industrial park.

Cambridge Science Park receives annual government funding, which is allocated to the salaries of high-caliber entrepreneurial mentors and management personnel, thereby facilitating more effective macro-level coordination. In terms of corporate management services, the park first provides startups with comprehensive administrative and social services (covering finance, information, technology trade, real estate, etc.) as well as municipal supporting facilities, creating a favorable innovation ecosystem for various innovative entities. Second, it actively establishes service platforms such as public scientific and technological resource platforms, specialized technical carriers, and public technology platforms to attract technology-based innovative enterprises to settle in the park.

So-called industrial agglomeration isAttract global professional organizations, subsidiaries of multinational corporations, and joint laboratories to establish a presence, leveraging global capital to rapidly establish the dominant industries within Cambridge Science Park. For instance, with the establishment of subsidiaries by multinational corporations such as Bayer and Amgen, Cambridge Science Park now hosts the largest cluster of biotechnology companies outside the United States. This also facilitates the aggregation of upstream, midstream, and downstream production factors in the bioscience sector, thereby attracting more innovative enterprises to set up operations there.

As a bridge connecting the University of Cambridge with industry, Cambridge Science Park prefers to describe itself as a “node” in the global new economy network.Engage in open exchanges with all economic entities pursuing technological and commercial interests.。

Within Cambridge Science Park, cluster learning mechanisms have been established, talent mobility is encouraged, and intermediary service institutions such as consulting and training firms are developed to facilitate knowledge dissemination and promote the transition of industrial clusters from individual and intra-organizational learning to cluster-based learning.

As new companies, talent, and investment are drawn to the area, they stimulate job creation and economic growth within Cambridge Science Park. In turn, the expansion of the Science Park provides innovative enterprises with greater opportunities to access a wider variety of suppliers, technical experts, and potential business partners.

From the perspective of researchers, what are the status and processes for technology transfer at the University of Cambridge?

Before establishing Mission Therapeutics, Professor Steve Jackson first disclosed and protected the intellectual property rights for first-in-class small-molecule drugs featuring selective targeting of deubiquitinating enzymes (DUBs) through his department’s technology transfer liaison. Subsequently, Cambridge Enterprise Ltd. planned and guided the commercialization of his research achievements on applying the ubiquitin pathway to the treatment of cancer and non-malignant diseases.

Researchers can appreciate the tangible support provided by Cambridge Enterprise Ltd.

Cambridge Enterprise Ltd.Cambridge Enterprise Ltd. is a wholly-owned subsidiary established by the University of Cambridge to oversee university-wide technology transfer and commercialization, dedicated to bringing the University’s research achievements to market. With commercialization as its core objective, Cambridge Enterprise Ltd. has established four business units:Technology Transfer Services(providing research and development funding support for researchers at the University of Cambridge),Consulting Services(Providing expert advice to researchers at the University of Cambridge),Seed Fund Services(Providing angel capital, early-stage investors, equity management, and other services through venture capital partners) andBasic Services(Customized management systems and best business practices).

In terms of technology transfer services, the University of Cambridge has established offices in every department, research institute, center, and laboratory.Liaison Officer, the liaison officer, approved by the department head, is specifically responsible for facilitating communication between the department’s research personnel and Cambridge Enterprise Ltd. Cambridge Enterprise Ltd. holds three meetings annually with liaison officers from all departments to discuss matters of mutual interest, and the University of Cambridge’s Vice-Chancellor for Research personally attends these meetings.

Each year, Cambridge Enterprise Ltd. receives more than 100 intellectual property disclosures and must decide within one month whether to file patent applications.

Due toIntellectual Property Rights Belong to the University of CambridgeOn one hand, Cambridge Enterprise Ltd. acts as the sole representative of the University of Cambridge in filing patents worldwide, with patent costs advanced by Cambridge Enterprise Ltd. and reimbursed by the enterprises receiving intellectual property licenses; on the other hand, regarding intellectual property licensing models, the University of Cambridge prioritizes non-exclusive licenses, thereby increasing the number of licensing agreements for the same intellectual property and boosting licensing revenue.

Patent applications are filed to promote the commercialization of research outcomes. Internally, the University of Cambridge categorizes patent commercialization into short-term and long-term approaches.

Short-term patent commercialization involves entering into collaborative agreements with enterprises, a rapid-cycle approach driven primarily by corporate needs; in contrast, the commercialization of basic research constitutes a long-term patent commercialization process, which represents the focal point of the University of Cambridge’s patent commercialization strategy.

Startups Need Financial Support the Most. Before external funding becomes available, the University of Cambridge first invests through its Proof of Concept Fund, Translation Fund, and Seed Fund to incubate start-ups founded by its faculty and students.

Among these, proof-of-concept funds may sometimes involve more than one round. Both proof-of-concept funds and translation funds are designed to help researchers develop product prototypes, thereby truly transforming ideas into products and commercial ventures.

Seed funds have a broader scope of application; they can be used not only for proof-of-concept and translation but also as pre-licensing intellectual property investments, pre-seed investments, and seed investments, helping startups navigate the "valley of death."

Upfront financial investment helps researchers validate the feasibility of their technologies while also advancing R&D at startups. The most direct return on this approach is evident in the 80% three-year survival rate of University of Cambridge startups, compared to the UK national average of just 58%.

Internally, the University of Cambridge has established a robust communication ecosystem between researchers and industry, facilitating immediate engagement when scientists achieve breakthroughs and express entrepreneurial intent. These initiatives are then screened and incubated through technology transfer mechanisms before being scaled up to broader platforms.

“As Dr. Diarmuid O’Brien, CEO of Cambridge University Enterprise Ltd., has stated, the Cambridge innovation ecosystem is home to a unique, driven community of distinguished scientists, individuals, companies, and partners who tackle global challenges and transform lives.”

Reference Article:

1. “Principal Zhang Fuli: Five Aspects of the University of Cambridge’s Innovation and Entrepreneurship System That We Cannot Replicate”

2. “Insights from the UK’s ‘Cambridge Model’”

3. “Cambridge University’s Experience in Technology Transfer and Commercialization”